Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7239361 versus placebo in ambulatory boys with Duchenne muscular dystrophy
NL-OMON48814Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2018
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of taldefgrobep alfa in Duchenne muscular dystrophy (DMD) (5 arms), sponsored by Roche. Primary endpoint: Change from baseline in North Star Ambulatory Assessment total score at Week 48. Started Aug 2018; status: active, not recruiting.
02
Drugs
taldefgrobep alfa
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON48814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48814.